Wednesday, March 11, 2026

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off

Right now, we’re witnessing a monumental shift in the world.

Artificial Intelligence is changing everything about the way people earn, spend, save, and invest their money.

The people who understand this stand to make an absolute mint!

It’s time to up your game… and jump straight in!

No matter whether you start with $50, $250, or $1,000…

Our No. 1 AI Pick is currently trading for pennies on the dollar compared to Nividia.

Nothing is guaranteed, but this is your chance to get in cheap and ride it to hundreds of dollars per share.

And here’s the great thing…

I’ll bet not one 1 in 10,000 investors knows about this scorching opportunity!

If you move quickly – before the mainstream press gets wind of what’s going on – this $3 AI Wonder Stock” could jumpstart the kind of carefree life you can only dream about right now.

But first, you’ll need to know its name and ticker symbol. 

Which we’re prepared to give you now when you watch this video bulletin.

Your friends, 

The Traders Agency Team

P.S. Grab your brand new 12-page Special Report called, The “$3 AI Wonder Stock” that Could Make You 75X Richer.

Full details are revealed in our special video presentation.


 
 
 
 
 
 

Just For You

Wendy's Is Down Sharply—Is the Dividend a Bargain or Value Trap?

By Chris Markoch. Article Posted: 3/1/2026.

Wendy’s Frosty held outside a Wendy’s restaurant, reflecting WEN stock focus and fast-food consumer demand.

Key Points

  • Wendy’s shares remain under heavy pressure despite a Q4 earnings beat, driven by the company’s worst same-store sales performance in two decades.
  • Management is pursuing store closures, menu value initiatives, and the “Project Fresh” overhaul as it navigates a strained lower-income consumer.
  • A 7%+ dividend yield may attract income investors, but weak growth guidance and declining free cash flow raise concerns about a value trap.
  • Special Report: [Sponsorship-Ad-6-Format3]

The Wendy’s Co. (NASDAQ: WEN) delivered a double beat when it reported Q4 2025 earnings on Feb. 13. Still, shareholders lost their appetite for WEN stock, which slid to a 52-week low of $6.73. Recent headlines have helped the stock stage a rally, but it remains down nearly 51% over the past 12 months and more than 61% over the last five years.

This is one of those situations where strong headline numbers didn’t soothe investors: Wendy’s posted its worst same-store sales performance in 20 years, and shareholders took notice.

Skip Headlines Straight to Original Research (Ad)

Our investment research analysts are going to be releasing their next investment idea tomorrow morning, around 10:00 AM Eastern time.

Add yourself to the distribution list here.tc pixel

That said, some investors see opportunity. Hedge fund billionaire Nelson Peltz, a major shareholder for over two decades, has been exploring ways to enhance shareholder value, and an SEC filing indicated a takeover could be among the options.

Wendy’s, however, is already executing a transformation under "Project Fresh" and has committed to closing between 5% and 6% of its locations in 2026. The company has also moved to make its value menu (for example, the Biggie Bag) more competitive.

What Peltz might try to unlock remains unclear; one potential change could be appointing a permanent chief executive officer (the company is currently led by interim CEO Ken Cook). For now, it’s prudent to evaluate the stock on its current fundamentals.

Turnaround Efforts Face Macro and Consumer Headwinds

Wendy’s beat on both the top and bottom lines, and those results were genuinely better than expected rather than merely better than feared. Still, the steep drop in same-store sales is difficult to ignore.

Interpreting the outlook is challenging. Economic commentary varies depending on which part of the "K-shaped" recovery one references: some consumer cohorts are holding up while lower-income consumers are clearly under pressure. When debates center on which $5 value meal offers the most perceived "value," the problem may lie more with consumers than with the company.

Add in concerns around GLP-1 medications and changing consumer preferences, and it’s understandable why Wendy’s performance looks strained. In 2021, the stock traded near $20—conditions have changed since then.

Wendy’s is forecasting roughly flat global sales and adjusted earnings per share of $0.56 to $0.60, which would be about a 32% decline at the high end of that range. The company plans to reduce capital expenditures by approximately $10 million to $20 million and expects free cash flow to fall to about $190 million from $205 million.

Those guidance items assume "more of the same," which may be a reasonable approach. 2026 looks like a year with a range of possible outcomes for the lower-income segment of the consumer base.

A Tasty Dividend or Value Trap?

One bright spot for WEN stock is its dividend.

The payout was cut nearly in half in 2025 but now stands at $0.56 per share. With the stock trading around $7.70 at the time of writing, that yields about 7.26%.

Whenever a report produces a high dividend yield, investors rightly ask about sustainability—especially given the forecasted drop in free cash flow. The current dividend costs Wendy’s roughly $106 million annually, which appears sustainable even with the projected decline in FCF.

The payout ratio is somewhat elevated at about 65.9% (investors generally prefer a ratio below 50%), but based on the company's conservative guidance, there’s no immediate evidence the dividend is unsafe.

Technical Picture Suggests Rally May Be Temporary

Technically, WEN has been in a steady downtrend since March 2025, falling from roughly $16 to current levels near $7.73. The stock has trended along the lower Bollinger Band for months and is now sitting near the 20-day simple moving average (SMA), approximately $7.82, which has acted as resistance during the decline.

After the sharp February sell-off and subsequent bounce, the price has mean-reverted to the middle Bollinger Band, suggesting the oversold condition from the pullback has already been relieved. That pattern points to the recent recovery being corrective rather than the start of a lasting reversal.

The moving average convergence/divergence (MACD) supports that view. While the MACD line briefly crossed above zero during the bounce, it is rolling back over and the signal line remains deeply negative (-0.1239). Resistance at the upper Bollinger Band (around $8.41) remains a key hurdle; without a convincing reclaim of that level, the path of least resistance still favors the downside.

Wendy’s (WEN) stock chart shows downtrend, MACD rollover and resistance near $8.41 upper Bollinger Band.

Bottom line: Wendy’s presents a mixed picture—an attractive yield underpinned by a manageable dividend cost, but meaningful sales weakness, margin pressure and a bearish technical backdrop. Investors should weigh the dividend and any potential activist-led changes against the operational and macro headwinds before deciding.


 

Just For You

Axon Got Caught in the SaaS Crash—Its Earnings Say That Was a Mistake

By Leo Miller. Article Posted: 2/26/2026.

Axon Enterprise logo over circuit board and city grid, highlighting AXON public safety tech and AI growth.

Key Points

  • Axon shares surged after Q4 earnings, snapping a months-long selloff that had cut the stock roughly in half from its all-time high.
  • The broader SaaS panic dragged Axon down alongside pure software names, but the company's hardware-integrated model may make that comparison a poor one.
  • Analysts still see meaningful upside even after trimming their price targets post-report.
  • Special Report: [Sponsorship-Ad-6-Format3]

After being battered in the second half of 2025 and again in early 2026, shares of defense company Axon Enterprise (NASDAQ: AXON) have sharply recovered. Following its Q4 financial results on Feb. 24, Axon shares jumped nearly 18% the next day.

Axon hit an all-time closing high near $871 last August. Before the latest earnings report, the stock had fallen roughly 50% from that peak.

Skip Headlines Straight to Original Research (Ad)

Our investment research analysts are going to be releasing their next investment idea tomorrow morning, around 10:00 AM Eastern time.

Add yourself to the distribution list here.tc pixel

Even after the recent rebound, Wall Street analysts remain generally bullish on the name.

So what drove Axon's steep sell-off, and are concerns about the company justified?

Axon's Sky-High P/E and the SaaS Sell-Off

Axon's sky-high forward price-to-earnings (P/E) ratio — which peaked near 130x in August — made the stock vulnerable to a correction. The company was also swept up in the 2026 "SaaSpocalypse," accelerating its decline.

Heading into the latest report, Axon shares were down more than 20% in 2026. Many of the stock's largest single-day losses coincided with steep drops across the software sector, suggesting AI-displacement fears affecting that industry also pressured Axon.

That broad-based sell-off, however, appears indiscriminate. Investors seemed to be selling software-related names en masse rather than assessing AI disruption risk on a case-by-case basis.

Why Axon's Hardware-to-Software Flywheel Insulates It From AI

Axon benefits from an important, durable reality: law enforcement requires physical action. AI cannot physically restrain or arrest someone, which limits AI-disruption risk for Axon's primary customers — police and public-safety agencies.

While Axon has a substantial software business that could theoretically face AI pressures, hardware remains central to its strategy. Consider the product that made Axon relevant: tasers. These are physical devices the company has developed for decades — something an AI startup can't replace with software alone.

Tasers continue to be a meaningful and fast-growing revenue stream. Sales of tasers grew 32% in Q4 2025, and hardware accounted for roughly one-third of Axon's full-year revenue. That leaves a large portion of the business less exposed to AI disruption.

Crucially, Axon's software is tightly integrated with its hardware. Body cameras capture video that feeds the company's digital evidence management platform, which generates subscription revenue. Other software products depend on the data those cameras produce.

For example, Draft One uses body-camera audio to create initial incident-report drafts, saving officers time over fully manual report writing so they can focus more on crime prevention and investigation.

To truly displace Axon's software, a competitor would likely need to replace its body-camera ecosystem as well. That would require agencies to rip out established systems, retrain personnel, and risk evidence-handling problems — all significant hurdles given Axon's entrenched trust with customers.

As Axon collects more data from its devices, its software should improve, creating a widening lead over competitors that lack that device-generated dataset.

Analysts See Significant Upside After Strong Results

Axon's latest earnings underscored the business's momentum. The company beat expectations on revenue and adjusted earnings per share (EPS), reporting revenue growth of 39%. Future contracted bookings — the value of signed contracts yet to be recognized — rose 43% to $14.4 billion, compared with $2.8 billion in total 2025 revenue, highlighting a sizable backlog.

Axon also reported a net revenue retention rate of 125%, meaning existing customers increased their spending by 25% year over year, which shows growing value from its offerings.

By 2028, Axon is targeting $6 billion in revenue, implying roughly 29% annual growth over the next three years. The company is also aiming to expand adjusted EBITDA margins by 250 basis points to 28%.

The MarketBeat consensus price target for Axon sits near $763, implying about 45% upside. After the report, analysts trimmed their targets; the average of updated targets is near $654, which still implies roughly 25% upside. Those downward adjustments largely reflect the stock's prior fall rather than a negative read on the report itself.

Overall, Axon's outlook appears promising, and fears of AI-driven disruption to its business seem overstated.


 

 
This email communication is a paid sponsorship for Traders Agency, a third-party advertiser of MarketBeat. Why did I receive this message?.
 
 
This ad is sent on behalf of Traders Agency, LLC, at 20 N Orange Ave Suite 1100, Orlando, FL 32801. If you're not interested in this opportunity from Traders Agency, LLC.
 
 
If you need assistance with your subscription, please email MarketBeat's South Dakota based support team at contact@marketbeat.com.
 
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
 
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103-7078. USA..
 
Today's Featured Link: Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why (From Banyan Hill Publishing)

No comments:

Post a Comment

5 things to know about Markwayne Mullin

Plus: Tucker Carlson, Talarico and Candace Owens ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌  ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌  ͏‌ ...